文献速递糖尿病

早期血糖控制与HbA1c降低幅度预测心血管事件和死亡:基于24,752名二甲双胍起始者的人群队列研究

Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators.
PubMed 文献 · Diabetes Care · 2017-04-12

该人群队列研究纳入北丹麦2000-2012年24,752名二甲双胍起始者,按起始后6个月HbA1c达标水平及较基线变化幅度分组,采用Cox回归分析后续急性心肌梗死、卒中或死亡风险。结果显示,与HbA1c<6.5%相比,达标水平越高风险逐渐增加;HbA1c降低幅度大者也与较低结局风险相关。

要点

  • 与HbA1c<6.5%相比,6.5-6.99%者复合结局调整HR 1.18(95%CI 1.07-1.30)。
  • HbA1c≥8%者复合结局调整HR 1.59(95%CI 1.37-1.84),风险随达标水平升高而增加。
  • 较基线HbA1c降低4%者复合结局调整HR 0.80(95%CI 0.65-0.97)。

核心结论

  • 二甲双胍起始后6个月内HbA1c降低幅度大且达到较低HbA1c水平,与2型糖尿病患者心血管事件和死亡风险较低相关。

研究设计与样本

  • 人群队列研究,纳入北丹麦2000-2012年所有伴有HbA1c检测的二甲双胍起始者,共24,752例,中位年龄62.5岁,男性55%,中位随访2.6年。

主要发现

  • 与目标HbA1c<6.5%相比,复合结局风险随达标HbA1c水平升高而逐渐增加:6.5-6.99%调整HR 1.18(95%CI 1.07-1.30),7.0-7.49% HR 1.23(1.09-1.40),7.5-7.99% HR 1.34(1.14-1.57),≥8% HR 1.59(1.37-1.84)。
  • 与HbA1c无变化(Δ=0)相比,较基线绝对降低幅度大者也预测结局:Δ=-4调整HR 0.80(0.65-0.97),Δ=-3 HR 0.98(0.80-1.20),Δ=-2 HR 0.92(0.78-1.08),Δ=-1 HR 0.99(0.89-1.10)。
  • 结果对于单个结局事件一致,并按年龄组和其他患者特征稳健。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We investigated the association of early achieved HbA1c level and magnitude of HbA1c reduction with subsequent risk of cardiovascular events or death in patients with type 2 diabetes who initiate metformin. RESEARCH DESIGN AND METHODS: This was a population-based cohort study including all metformin initiators with HbA1c tests in Northern Denmark, 2000-2012. Six months after metformin initiation, we classified patients by HbA1c achieved (<6.5% or higher) and by magnitude of HbA1c change from the pretreatment baseline. We used Cox regression to examine subsequent rates of acute myocardial infarction, stroke, or death, controlling for baseline HbA1c and other confounding factors. RESULTS: We included 24,752 metformin initiators (median age 62.5 years, 55% males) with a median follow-up of 2.6 years. The risk of a combined outcome event gradually increased with rising levels of HbA1c achieved compared with a target HbA1c of <6.5%: adjusted hazard ratio (HR) 1.18 (95% CI 1.07-1.30) for 6.5-6.99%, HR 1.23 (1.09-1.40) for 7.0-7.49%, HR 1.34 (1.14-1.57) for 7.5-7.99%, and HR 1.59 (1.37-1.84) for ≥8%. Results were consistent for individual outcome events and robust by age-group and other patient characteristics. A large absolute HbA1c reduction from baseline also predicted outcome: adjusted HR 0.80 (0.65-0.97) for Δ = -4, HR 0.98 (0.80-1.20) for Δ = -3, HR 0.92 (0.78-1.08) for Δ = -2, and HR 0.99 (0.89-1.10) for Δ = -1 compared with no HbA1c change (Δ = 0). CONCLUSIONS: A large initial HbA1c reduction and achievement of low HbA1c levels within 6 months after metformin initiation are associated with a lower risk of cardiovascular events and death in patients with type 2 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Svensson E, Baggesen LM, Johnsen SP, et al. Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators. Diabetes Care. 2017. PMID: 28404659. doi:10.2337/dc16-2271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。